ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster Buys 60,000 Shares

ProMIS Neurosciences, Inc. (NASDAQ:PMN - Get Free Report) Director Madge K. Shafmaster acquired 60,000 shares of the company's stock in a transaction on Friday, September 20th. The shares were acquired at an average cost of $1.25 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director now owns 68,333 shares of the company's stock, valued at $85,416.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

ProMIS Neurosciences Stock Up 5.7 %

NASDAQ PMN opened at $1.30 on Wednesday. The firm has a market cap of $24.65 million, a P/E ratio of -1.76 and a beta of 0.62. The company's 50 day moving average is $1.41 and its 200-day moving average is $1.72. ProMIS Neurosciences, Inc. has a 12-month low of $0.95 and a 12-month high of $3.10.

ProMIS Neurosciences (NASDAQ:PMN - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. Equities analysts expect that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current year.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.

Read More

• Five stocks we like better than ProMIS Neurosciences
• The Basics of Support and Resistance
• Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
• What is Short Interest? How to Use It
• Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
• What is a buyback in stocks? A comprehensive guide for investors
• Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

More From MarketBeat

Musk Says ‘Dollar Will Be Worth Nothing…’

Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…

Crypto 101 Media | Sponsored

7 Defense Stocks That Don’t Need the Election to Move Higher

The defense sector is a good place for investors who are looking for both growth and value. While it's not one...

MarketBeat

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...

Paradigm Press | Sponsored

7 Infrastructure Stocks to Buy Like There's No Tomorrow

Members of Congress agree on very few things. But in the last four years, there has been bipartisan support fo...

MarketBeat

How a $200,000 Mistake Unlocked a $118 Billion Gold Treasure

The window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.

Monument Traders Alliance | Sponsored

7 Downgraded Stocks That Still May Be Worth a Look

A key reason a stock price drops is one or more analyst downgrades. An analyst typically downgrades a stock be...

MarketBeat

Notice: Major payout due November 19th - are you on the list?

On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's p...

Behind the Markets | Sponsored

15 REITs That Wall Street Analysts Love in Today's Market

There are more than 200 publicly-traded real-estate investment trusts (REITs) that you can buy through your br...

MarketBeat